A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

Benjamin A. Weinberg,Hongkun Wang,Agnieszka K. Witkiewicz,John L. Marshall,Aiwu R He,Paris Vail,Erik S. Knudsen,Michael J Pishvaian

A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

2020

Benjamin A. Weinberg
Hongkun Wang
Agnieszka K. Witkiewicz
John L. Marshall
Aiwu R He
Paris Vail
Erik S. Knudsen
Michael J Pishvaian

Purpose: Metastatic pancreatic adenocarcinoma (mPC) has a poor prognosis. CDK4/6 is often deregulated in mPC due to CDKN2A loss, resulting in the loss of p16INK4a that inhibits CDK4/6. CDK4/6 inhib...

Keywords:

Metastatic Pancreatic Adenocarcinoma
Refractory
Ribociclib
Everolimus
in patient
Oncology
phase i study
Medicine
Chemotherapy
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations